COX-2 Inhibitors and Bone Healing

Research has long shown that inflammation plays a necessary role in bone repair. A study published in the Journal of Bone and Mineral Research (2002;17:963) examined how selective COX-2–inhibiting anti-inflammatory drugs affect fracture healing.

COX-2 inhibitors were developed to reduce pain and inflammation while minimizing gastrointestinal side effects seen with older NSAIDs. However, this research found that blocking COX-2 can significantly impair bone repair.

In animal models, traditional NSAIDs such as ibuprofen and indomethacin caused only a modest delay in bone healing. In contrast, strong COX-2 inhibition markedly disrupted the healing process, in some cases preventing normal bone repair altogether.

Although the specific drug Vioxx (rofecoxib) was later withdrawn from the market due to cardiovascular risk, the mechanism identified in this research remains relevant. Celecoxib (Celebrex) and other COX-2–selective drugs are still in use today, and subsequent research has continued to raise concerns about fracture healing, spinal fusion outcomes, and post-surgical bone repair when COX-2 inhibitors are used aggressively or long-term.

Practical Takeaway

Pain control after fractures or orthopedic surgery must balance comfort with biology. While anti-inflammatory medications can reduce pain, excessive suppression of inflammation—especially via COX-2 inhibition—may interfere with the body’s ability to heal bone.

This has led many clinicians to favor:

  • Short-term use only,

  • Lower doses when possible, and

  • Non-drug strategies to support healing, including nutrition, mechanical loading, and manual therapies.